Journal
ONCOGENE
Volume 27, Issue 27, Pages 3870-3874Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2008.13
Keywords
her2; Pertuzumab; heterodimer; 4D5
Funding
- NCI NIH HHS [5P01 CA89480, P01 CA089480-04, P01 CA089480] Funding Source: Medline
Ask authors/readers for more resources
2C4 ( Pertuzumab, Omnitarg) is a monoclonal antibody targeting p185(her2/neu), which is overexpressed in 30% of invasive breast cancer. 2C4 is currently in phase II clinical trials for several types of cancers. This antibody has been reported to disrupt the association between p185(her2/neu) and ErbB3. In our studies of epidermal growth factor receptor ( EGFR)-p185(her2/neu) heterodimerization, we noted that 2C4 formed associations with the EGFR-p185(her2/neu) receptor complex. Our data argue against 2C4 as a universal heterodimerization blocker for p185(her2/neu), but indicate that cocktails of monoclonal antibodies binding distinct interaction surfaces of p185(her2/neu) will emerge as the most potent targeted therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available